Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …

Background Patient‐reported outcome measures (PROMs) are questionnaires that collect
health outcomes directly from the people who experience them. This review critically …

Background A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–
associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …

Background The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved
for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have …

PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …

PURPOSE To update the ASCO guideline (2018) on the practical assessment and
management of age-associated vulnerabilities in older patients undergoing systemic cancer …

Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial
carcinoma, but positive randomised data supporting their use as a first-line treatment are …

Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine
is the standard first-line chemotherapy regimen, but no robust evidence is available for …

Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20%
of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free …

Importance Robot-assisted radical cystectomy is being performed with increasing frequency,
but it is unclear whether total intracorporeal surgery improves recovery compared with open …